Sheet 1 of 3 APPLICATION NO ATTY DOCKET NO. 11183-010-999 10/643,857 (505421-999009) EFERENCES CITED BY APPLICANT APPLICANT (Use several sheets Emecessary) Scott Koenig and Maria Concetta Veri GROUP ROV 1 6 2004 August 14, 2003 1641 MADEMARK **U.S. PATENT DOCUMENTS** FILING DATE IF APPROPRIATE CLASS SUBCLASS NAME DOCUMENT NUMBER DATE MATTER Davis et al. 4,179,337 12/18/79 AOI 01/27/98 Gilbert et al. 5,711,944 A02 03/30/99 Dunn 5,888,533 A03 997 07/15/99 Winter et al. 5,648,260 A04 08/31/99 Dunn et al. 5,945,115 A05 6,019,968 02/01/00 Platz et al. A06 10/17/00 Li et al. 6,132,764 A07 6,194,551 02/27/01 Idusogie et al. A08 04/17/01 Morrison et al. 6,218,149 A09 2001/0036459 11/01/01 Ravetch A 10 01/15/02 Meers et al. 6,339,069 AII 2002/0028486 03/07/02 Morrison et al. A12 6,420,149 07/16/02 Fukuda et al. A13 6,472,511 10/29/02 Leung et al. A14 03/04/03 Idusogie et al. 6,528,624 A15 Kanda et al. 06/19/03 2003/0115614 A16 FOREIGN PATENT DOCUMENTS TRANSLATION CLASS SUBCLASS MATTER DOCUMENT NUMBER DATE COUNTRY YES NO PCT 08/18/94 BOI WO 94/18330 EPC EP 0 359 096 11/05/97 B02 07/20/00 PCT WO 00/42072 **B03** EPC EP 0 343 950 B1 10/18/00 **B**04 PCT WO 03/035835 05/01/03 B05

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
C.	$C_{ij}$		Abra et al. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically- stabilized immunoliposomes and active-loading gradients. J Liposome Res. 2002 Feb-May;12(1-2):1-3					
			Bendas G, Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15(4):215-24.					
		C03	Billadeau et al., ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest. 2002 Jan;109(2):161-8.					
			Bolland and Ravetch. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. 1999;72:149-177.					
t	٠C٠		Bolland et al. Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med. 2002 May 6;195(9):t167-74					
		C06	Boruchov et al., Expression and modulation of the inhibitory Fegamma receptor, FegammaRIIb (CD32b), on human dendritie cells (DCs). Laboratory of Cellular Immunobiology, Department of Medicine, Memorial Sloan-Kettering					
- T			Cancer Center, NY, NY 10021					

AE 1-30/ 1-08

OIPE TO SE
PATTA TRADEMEN

	Express Mail No. EV 452 775 784 US Sheet 1 of 1											
PART & TRI				ATTY DOCKET NO. 11183-010-999			APPLICATION NO					
LIST	COFI	REFERENCES CITI	ED BY APP	LICANT	APPLICANT	10/643,857						
		(Use several sheets if		2.0	Koenig et al.							
					FILING DATE August 14, 2005	FILING DATE August 14, 2005		GROUP 1644				
			U.S. PA	TENT DOCU			····	<del></del>				
144	T	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING D				
C.C.	A17	5,837,243 1998	11/17/1997	Deo et al.	NAME	CLASS	SUBCLASS	IF AFFROR	MAIL			
	1		<del> </del>									
									-			
FOREIGN PATENT DOCUMENTS												
MATTER		DOCUMENT NUMBER	DATE	<u> </u>	COUNTRY	CLASS	SUBCLASS		T			
OC.	B06	WO 99/58572 A1	11/18/1999	РСТ			T	YES	NO			
C.C.	B07	WO 01/79299 A1	10/25/2001	PCT					<b> </b>			
C.C.	B08	WO 03/066095 A2	08/14/2003	PCT			1	<del> </del>				
C.C.	B09	EP 1 006 183 A1	06/07/2000	EP								
		OTHER REFERE	ENCES (Incli	uding Author,	Title, Date, Pertinent	Pages,	Etc.)					
e.c.	C71	Ding et al., Inhibition of antigen. Immunology. 2	the function of t 001 Sep;104(1	he FcyRIIB by a r ):28-36	nonoclonal antibody to th	ymic shan	ed antigen-1,	a Ly-6 fam	ily "			
								·				
	<u> </u>											
	ļ							<del> </del>				
	ļ	<del></del>										
					<u> </u>		<del> ·</del>					
	<u> </u>					, , ,						
EXAMINER		a g		DAT	E CONSIDERED 9	141	27					
*EXAMINER: considered. Inc	Initial if lude cop	reference considered, whether y of this form with next comm	or not citation is unication to applic	in conformance with	MPEP 609; Draw line thro	ugh citation	if not in confe	ormance and	not			